Johnson & JohnsonvsKura Oncology

JNJ and KURA stock compared: price, dividend, valuation and results, from SEC filings.

Johnson & Johnson (JNJ) has a market value of $652B and Kura Oncology (KURA) $610M. Over the last year, with dividends, JNJ moved +36.6% and KURA -39.0%. Dividend yield: JNJ 1.95%, KURA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    KURA$610M

    JNJ is 1,068 times KURA

  • Revenue, 12 months

    JNJ$99.3B

    KURA$79M

    JNJ is 1,252 times KURA

  • Net income, 12 months

    JNJ$16.1B

    KURA-$293M

  • Operating margin

    JNJ–

    KURA-394.3%

  • ROIC

    JNJ12.4%

    KURA-192.2%

    204.6 points apart

  • P/E

    JNJ40.5

    KURA–

  • Dividend yield

    JNJ2.0%

    KURA0.0%

    2.0 points apart

  • 5-year return

    JNJ+90.9%

    KURA-59.3%

    150.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+90.9%

KURA-59.3%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsKURAWith dividends
1 year since November 19, 2025+36.6%Price +33.6%-39.0%Price -39.0%
3 years since November 20, 2023+94.9%+24.9% a yearPrice +80.4%-27.6%-10.2% a yearPrice -27.6%
5 years since November 19, 2021+90.9%+13.8% a yearPrice +66.0%-59.3%-16.5% a yearPrice -59.3%
10 years since November 21, 2016+206.5%+11.9% a yearPrice +135.2%+25.6%+2.3% a yearPrice +25.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonKURAKura Oncology

Valuation

JNJKURA
Valuation
Price$270.47$6.91
Market value$652B$610M
Enterprise value (EV)$679B–
P/E40.5–
P/E, 5-year median21.9–
P/B8.034.0
EV/EBIT38.3–
Free cash flow yield3.2%–

Results and growth

JNJKURA
Results and growth
Revenue, 12 months$99.3B$79M
Net income, 12 months$16.1B-$293M
Free cash flow, 12 months$20.6B-$89M
Earnings per share, 12 months$6.59-$3.30
Revenue growth, year on year6.1%25.2%
Revenue growth a year, past+2.7%over 5 years–
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJKURA
Margins and returns on capital
Gross margin67.6%–
Operating margin–-394.3%
Net margin16.2%-369.3%
ROIC12.4%-192.2%
ROE19.7%-247.8%

Balance sheet

JNJKURA
Balance sheet
Cash$17.2B$492M
Total debt$44.7B–
Net debt / EBITDA1.1–
Interest cover18.0×-227.1×

Dividends and buybacks

JNJKURA
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or KURA

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Kura Oncology?

By market value, Johnson & Johnson ($652B) is about 1,067.9 times Kura Oncology ($610M), at today's prices.

How did JNJ and KURA stock do over the last 10 years?

Since November 21, 2016, JNJ's price moved +135.2% and KURA's +25.6%. With dividends: JNJ +206.5% (+11.9% a year), KURA +25.6% (+2.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or KURA?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Kura Oncology. Over the last twelve months they paid $5.28 and – per share.

Which has the higher profit margins, Johnson & Johnson or Kura Oncology?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and -369.3% for Kura Oncology, and the operating margin – and -394.3%. Revenue was $99.3B and $79M.

Which is the better investment, Johnson & Johnson or Kura Oncology?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.